Pathogenic, criteria provided, single submitter | clinical testing | Rady Children's Institute for Genomic Medicine, Rady Children's Hospital San Diego | May 28, 2018 | This variant has been previously reported in the Human Gene Mutation Database (HGMD) and has been described as a recurrent de novo heterozygous change in patients with macrocephaly, developmental delay, hypotonia, and EEG abnormalities (PMID: 26168268, 28554332, 28628100, 25972378, 29296277). The c.592G>A (p.Glu198Lys) variant affects a highly conserved amino acid and is predicted by multiple in silico tools to have a deleterious effect on protein function. Functional analysis of cells expressing the p.Glu298Lys variant showed deficient PP2A holoenzyme formation (PMID: 26168268). This change is absent from the ExAC and gnomAD population databases and thus is presumed to be rare. Analysis of the parental samples was negative for the variant, indicating this variant likely occurred as a de novo event. Based on the available evidence, the c.592G>A (p.Glu198Lys) variant is classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Center for Molecular Medicine, Children’s Hospital of Fudan University | Dec 25, 2020 | - - |
Pathogenic, no assertion criteria provided | clinical testing | Pediatric Genetics Clinic, Sheba Medical Center | May 13, 2021 | - - |
Pathogenic, no assertion criteria provided | provider interpretation | GenomeConnect - Simons Searchlight | Mar 25, 2019 | Submission from Simons Searchlight facilitated by GenomeConnect. Variant interpreted by the Simons Searchlight team most recently on 2019-03-25 and interpreted as Pathogenic. The reporting laboratory might also submit to ClinVar. This variant was identified in multiple probands enrolled in Simons Searchlight. - |
Pathogenic, criteria provided, single submitter | research | HudsonAlpha Institute for Biotechnology, HudsonAlpha Institute for Biotechnology | Feb 11, 2016 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Oct 30, 2018 | Variant summary: PPP2R5D c.592G>A (p.Glu198Lys) results in a conservative amino acid change (however with charge reversal) in a highly conserved acidic loop that faces and directly interacts with the catalytic subunit of PP2A; and a charge alteration in this acidic surface could potentially interrupt subunit interactions (Houge 2015). Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant was absent in 246254 control chromosomes (gnomAD). The variant, c.592G>A, has been reported in the literature as a de novo mutation in multiple individuals affected with Mental retardation, autosomal dominant 35 (MRD35) (Houge 2015, Loveday 2015). These data indicate that the variant is very likely to be associated with disease. At least one of these publications also reported experimental evidence evaluating an impact on protein function, demonstrating loss of binding to the catalytic subunit, which leads to a defect in PP2A-B56delta-dependent dephosphorylation activity (Houge 2015). Five clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as pathogenic (4x) / likely pathogenic (1x). Based on the evidence outlined above, the variant was classified as pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Institute of Human Genetics, University of Leipzig Medical Center | Feb 07, 2023 | _x000D_ Criteria applied: PS2, PS3, PS4_MOD, PM1, PM2_SUP, PP3 - |
Pathogenic, criteria provided, single submitter | clinical testing | Department of Human Genetics, Hannover Medical School | May 22, 2023 | - - |
Likely pathogenic, no assertion criteria provided | clinical testing | Genomics England Pilot Project, Genomics England | - | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Institute of Human Genetics Munich, Klinikum Rechts Der Isar, TU München | Jan 16, 2018 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | 3billion | Oct 02, 2021 | Same nucleotide change resulting in same amino acid change has been previously reported as de novoo and observed in at least four similarly affected unrelated individuals (PMID: 26168268, 25972378, PS2 and PS4). The missense variant is located in a mutational hot spot and/or well-established functional domain in which established pathogenic variants have been reported (PM1). It is not observed in the gnomAD v2.1.1 dataset (PM2). The variant was observed as assumed (i.e. paternity and maternity not confirmed) de novoo (3billion dataset, PM6). Therefore, this variant is classified as pathogenic according to the recommendation of ACMG/AMP guideline. - |
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Apr 04, 2023 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Greenwood Genetic Center Diagnostic Laboratories, Greenwood Genetic Center | Oct 04, 2023 | PS2, PS3, PS4, PM1, PM2, PP2, PP3 - |
Pathogenic, criteria provided, single submitter | clinical testing | New York Genome Center | Jun 11, 2021 | The de novo heterozygous c.592G>A (p.Glu198Lys) missense variant identified in the PPP2R5D gene is a known recurrent de novo pathogenic variant and has been reported in multiple unrelated individuals [PMID:28554332; PMID:28191890; PMID: 29296277; PMID: 26168268]. It is the most frequently identified variant in patients affected with PPP2R5D-Related neurodevelopmental disorder [PMID:30676711]. The variant has been reported as Pathogenic in ClinVar database [Variation ID: 190286]. The variant is absent from gnomAD(v3) database suggesting it is not a common benign variant inthe populations represented in that database. The variant affects an evolutionarily conserved residue and is predicted deleterious by multiple in silico predictiontools. In vitro functional studies showed that the p.Glu298Lys variant results in deficient PP2A holoenzyme formation [PMID: 26168268]. Based on the available evidence, the de novo heterozygous c.592G>A (p.Glu198Lys) missense variant identified in the PPP2R5D gene is reported as Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Victorian Clinical Genetics Services, Murdoch Childrens Research Institute | Feb 02, 2022 | Based on the classification scheme VCGS_Germline_v1.3.4, this variant is classified as Pathogenic. Following criteria are met: 0105 - The mechanism of disease for this gene is not clearly established. Dominant negative is a proposed mechanism of disease in this gene and is associated with PPP2R5D-related intellectual disability (MIM#616355). Missense variants in transfected HEK293 cells have demonstrated an inability to assemble into a holoenzyme complex however, co-expression with wildtype protein was not performed. Loss of function is also a potential mechanism (PMID: 32074998, PMID: 26168268). (I) 0107 - This gene is associated with autosomal dominant disease. (I) 0200 - Variant is predicted to result in a missense amino acid change from glutamic acid to lysine. (I) 0251 - This variant is heterozygous. (I) 0301 - Variant is absent from gnomAD (both v2 and v3). (SP) 0309 - An alternative amino acid change at the same position has been observed in gnomAD (v3) (1 heterozygote, 0 homozygotes). (I) 0502 - Missense variant with conflicting in silico predictions and uninformative conservation. (I) 0602 - Variant is located in a hotspot region or cluster of pathogenic variants (DECIPHER). (SP) 0801 - This variant has strong previous evidence of pathogenicity in unrelated individuals. This variant has been reported many times as pathogenic, and has been observed as de novo in multiple individuals with intellectual disability, macrocephaly, hypotonia and developmental delay (ClinVar, GeneReviews). (SP) 1203 - This variant has been shown to be de novo in the proband (parental status confirmed, by trio analysis). (SP) Legend: (SP) - Supporting pathogenic, (I) - Information, (SB) - Supporting benign - |
not provided, no classification provided | literature only | GeneReviews | - | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Equipe Genetique des Anomalies du Developpement, Université de Bourgogne | Jan 01, 2015 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Génétique des Maladies du Développement, Hospices Civils de Lyon | Jun 21, 2018 | - - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Aug 03, 2015 | - - |